ArticleCancer reports (Hoboken, N.J.)2025
Targeting the mTOR Signaling Pathway Through miR-100 and miR-101 in De Novo Acute Myeloid Leukemia: Implications for Therapeutic Intervention.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Investigating autophagy and miRNAs as therapeutic targets in leukemia.Discover oncology · 2026Review
- Non-coding RNA biomarkers in resistant hypertension: a scoping review.Frontiers in molecular biosciences · 2026Review
- Targeting the mTOR Signaling Pathway Through miR-100 and miR-101 in De Novo Acute Myeloid Leukemia: Implications for Therapeutic Intervention.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroribonucleic acid (MicroRNAs/miRNAs) play a significant role in cancer progression by changing cellular functions through the modulation of protein expressions. The potential of different miRNAs to alter the expression of the mammalian target of rapamycin (mTOR)/protein kinase B (PKB or AKT)/phosphatidylinositol-3-kinase (PI3K) signaling cascade, a key pathway in the progression of acute myeloid leukemia (AML), has been demonstrated across different types of cancers.
aimsThis study aims to explore the effects of miR-100 and miR-101 on the mTOR/AKT/PI3K signaling pathway in AML. METHODS AND
resultsInitially, we employed the TargetScan, miRDB, and miRanda databases to identify the target proteins of miR-100 and miR-101. Following a comprehensive analysis, we identified the mTOR/AKT/PI3K signaling pathway as a significant target for investigation in patients with AML. In this case-control study, the expression levels of miRNAs and genes were analyzed in 21 AML patients and 9 healthy controls using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The results showed that miR-100 was significantly upregulated, while miR-101, mTOR, and PI3K were downregulated in AML patients. Correlation analysis revealed a negative relationship for miR-100 and a positive one for miR-101 with mTOR, but no significant correlation with AKT1 and PI3K genes.
conclusionThese findings suggest that both miR-100 and miR-101 act as tumor suppressors via the mTOR/AKT/PI3K signaling pathway, highlighting their potential as therapeutic targets in AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.